Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.
Identifieur interne : 000F02 ( Main/Exploration ); précédent : 000F01; suivant : 000F03Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.
Auteurs : RBID : pubmed:22399599English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , metabolism : Indium Radioisotopes, Somatostatin, Yttrium Radioisotopes.
- metabolism : Kidney.
- Animals, Male, Rats, Rats, Wistar.
Abstract
Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As (90)Y emits no gamma rays, absorbed doses for (90)Y are usually estimated using the same peptide labelled with (111)In. The aim of the study was to determine if replacement of (90/88)Y by (111)In affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments.
PubMed: 22399599
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.</title><author><name sortKey="Laznicek, Milan" uniqKey="Laznicek M">Milan Laznicek</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Charles University, Heyrovskeho 1203, CZ-50005 Hradec Kralove, Czech Republic. laznicek@faf.cuni.cz</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Faculty of Pharmacy, Charles University, Heyrovskeho 1203, CZ-50005 Hradec Kralove</wicri:regionArea></affiliation></author><author><name sortKey="Laznickova, Alice" uniqKey="Laznickova A">Alice Laznickova</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="RBID">pubmed:22399599</idno><idno type="pmid">22399599</idno><idno type="wicri:Area/Main/Corpus">000E49</idno><idno type="wicri:Area/Main/Curation">000E49</idno><idno type="wicri:Area/Main/Exploration">000F02</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Indium Radioisotopes (metabolism)</term><term>Kidney (metabolism)</term><term>Male</term><term>Rats</term><term>Rats, Wistar</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (metabolism)</term><term>Yttrium Radioisotopes (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Indium Radioisotopes</term><term>Somatostatin</term><term>Yttrium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Kidney</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Male</term><term>Rats</term><term>Rats, Wistar</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As (90)Y emits no gamma rays, absorbed doses for (90)Y are usually estimated using the same peptide labelled with (111)In. The aim of the study was to determine if replacement of (90/88)Y by (111)In affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22399599</PMID><DateCreated><Year>2012</Year><Month>03</Month><Day>08</Day></DateCreated><DateCompleted><Year>2012</Year><Month>05</Month><Day>08</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7530</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Anticancer research</Title><ISOAbbreviation>Anticancer Res.</ISOAbbreviation></Journal><ArticleTitle>Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.</ArticleTitle><Pagination><MedlinePgn>815-22</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As (90)Y emits no gamma rays, absorbed doses for (90)Y are usually estimated using the same peptide labelled with (111)In. The aim of the study was to determine if replacement of (90/88)Y by (111)In affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Radiolabelled peptides were administered intravenously to male Wistar rats.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The peptides under study labelled either with (111)In or with (88/90)Y showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for (88/90)Y-labeled peptide in comparison with the one of (111)In.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We conclude that a radiation-absorbed dose after (90)Y-labelled somatostatin analogues appears to be lower than that predicted by the (111)In-labelled peptide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laznicek</LastName><ForeName>Milan</ForeName><Initials>M</Initials><Affiliation>Faculty of Pharmacy, Charles University, Heyrovskeho 1203, CZ-50005 Hradec Kralove, Czech Republic. laznicek@faf.cuni.cz</Affiliation></Author><Author ValidYN="Y"><LastName>Laznickova</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Anticancer Res</MedlineTA><NlmUniqueID>8102988</NlmUniqueID><ISSNLinking>0250-7005</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Yttrium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kidney</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Yttrium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">32/3/815</ArticleId><ArticleId IdType="pubmed">22399599</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22399599
|texte= Different radioactivity uptake between somatostatin analogues labelled with ¹¹¹In and ⁹⁰/⁸⁸Y in rat kidney.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22399599" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |